key: cord-0041716-grw8etab
authors: Simpson‐Haidaris, Patricia J.; Sahni, Abha
title: Author's reply to Weijers et al. “Fibrin β(15–42) domain is cryptic in intact fibrinogen: comment on the study by A. Sahni et al.”
date: 2010-03-02
journal: Int J Cancer
DOI: 10.1002/ijc.25288
sha: ceb861e3091278448ae82342daf3d093fe7b98d2
doc_id: 41716
cord_uid: grw8etab

nan

With interest we read the article by Abha Sahni and coworkers; ''The VE-cadherin binding domain of fibrinogen induces endothelial barrier permeability and enhances transendothelial migration of malignant breast epithelial cells'' in the edition of August 1st, 2009. 1 Sahni et al. showed that addition of intact fibrinogen induces an increase in endothelial permeability. This increase was shown to be mediated via binding of fibrinogen domain b to VE-cadherin on endothelial cells. Transendothelial migration of malignant breast cancer cells was increased by fibrinogen. The data provide novel insight in transendothelial migration of malignant cells, which require fibrinogen domain b and VE-cadherin binding.

Sahni et al. showed a significantly increased permeability of human endothelial cells using 300 nM (0.1 g/L) fibrinogen. This is a surprising finding, since this is below the fibrinogen concentrations in the human circulation. In our own experiments, 50 and 200 nM intact fibrinogen showed no increase in permeability of the endothelial monolayer, using highly purified intact fibrinogen fractions (unpublished). Published data on higher fibrinogen concentrations do not show a consensus on whether the intact protein increases vascular permeability. Tyagi et al. showed that at pathologically high levels, fibrinogen (12 lM) can increase permeability of the endothelial monolayer, whereas physiological concentrations (6-12 lM) had no effect. 2 Here, Sahni et al. showed an induction of endothelial permeability using 300 nM fibrinogen. Referring to the human circulation, it would be surprising if fibrinogen concentrations beneath physiological levels would be able to increase permeability. Therefore, we carefully compared the experiments and proposed mechanism.

The fibrinogen-induced permeability was investigated using peptides and blocking antibodies. Sahni et al. showed an impaired fibrinogen-induced permeability after addition of antibody T2G1 excess. This suggests that the antibody T2G1 bound intact fibrinogen and thereby impaired endothelial permeability. However, Kudryk et al. showed that the monoclonal antibody T2G1 only binds b 15-21 on fibrin and its degradation products, whereas the binding to intact fibrinogen was shown to be 250 times lower. 3 Moreover, peptide b 15-42 was shown to mimic fibrinogen-induced permeability, but the control peptide had no effect. 1 As stated in the introduction, domain b 15-42 is cryptic in fibrinogen and exposed after cleavage of fibrinopeptide B or proteolytic degradation. 1, 4 Domain b 15-42 is also being exposed after thrombin-independ-ent fibrinogen matrix assembly. 5 In the methods of the article, it was described that intact soluble fibrinogen was added to the apical side of the endothelial monolayer. The question rises whether fibrinogen domain b 15-42 was exposed and bound to endothelial VE-cadherin to increase permeability. The role of VE-cadherin regulating permeability in the endothelial cell junctions has been extensively studied. 6 Moreover, as shown by Ge et al., relatively low concentrations fibrin degradation products increase endothelial permeability. It was shown that 0.5-2.0 lM (0.05-0.2 g/L) fragment D caused a doubling of the transendothelial 125 I-albumin clearance in 2 hr. 7 Healthy individuals have D-dimer concentrations with a maximum of 0.0005 g/L. Taken together, these findings strongly suggest the presence of fibrin monomers or fibrin degradation products in the fibrinogen sample used by Sahni et al. Alternatively, the exposure of cryptic domains within the fibrinogen molecule by conformational changes may contribute to the exposure of fibrin specific epitopes, such as is also observed after fibrinogen binding to plastic culture plates.

The mechanism proposed by Sahni et al. is that tumorassociated fibrinogen can facilitate transendothelial migration of malignant cells. Intact fibrinogen would increase vascular permeability via binding of fibrinogen domain b 15-42 to endothelial VE-cadherin. However, domain b 15-42 was shown to be cryptic in intact fibrinogen. 3 In our opinion, not intact fibrinogen but fibrin or its degradation products are responsible for the observed effects. This sheds a new light on the data. Palumbo et al. showed that fibrin(ogen) is an important determinant of the metastatic potential of tumor cells. In wild-type mice, a 20-fold reduction of tumor metastasis was seen after addition of the thrombin-inhibitor hirudin. 8 In addition to a contribution of fibrinogen to platelet-microthrombi, which may provide protection to tumor cells against innate immune surveillance systems, 9 Sahni et al. proposed that tumor-associated fibrinogen can facilitate transendothelial migration of malignant cells. Our addition to the latter proposed mechanism would be that tumor-associated fibrinogen is converted to fibrin monomers or fibrin degradation products. Thereafter, it acts as a bridging molecule between tumor cells and endothelial cells, after which transendothelial migration can take place. The bridging of fibrin to VE-cadherin on endothelial cells is mediated via domain b 15-42 on the molecule.

In summary, findings demonstrating that relatively low concentrations of intact fibrinogen increase permeability should be reconsidered. Domain b 15-42 is exposed after thrombin cleavage and degradation of fibrin, thereafter the fibrin specific antibody T2G1 can bind. The results shown by Sahni et al. strongly suggest the presence of fibrin specific epitopes, which bear impact on the interpretation of the data. In this view, not intact fibrinogen but fibrin monomers or fibrin degradation products form the bridging molecule between tumor and endothelial cells. 1 Moreover, we appreciate the concerns raised by Weijers et al. 2 that the effects we observed on endothelial permeability and malignant breast epithelial cell transendothelial cell migration were due to thrombin/proteolytic conversion of the exogenously added fibrinogen to fibrin monomer and/or fibrin(ogen) degradation products and not due to the exposure of the cryptic vascular endothelial (VE)-cadherin binding domain located at residues 15-42 on the b chain of intact fibrinogen. Although a role for VE-cadherin in regulating endothelial cell permeability is well established, 3 a role for intact fibrinogen in the absence of its conversion to fibrin and/or fibrin(ogen) degradation products to promote endothelial cell permeability would be unexpected.

When we initiated these studies, we also expected that only fibrin monomer and fibrin(ogen) degradation products, as previously reported in the literature, and as cited by Weijers etal, 2 would induce permeability of barrier endothelium. The commercially purchased highly purified fibrinogen used in all of our studies is subjected to additional rigorous quality control as described. 1 Although small amounts of fibrin I and fibrin II as well as some fibrin(ogen) degradation products are found in commercial sources of purified human fibrinogen prepared from pooled plasma, we are convinced there is negligible contamination with fibrin monomer and/or fibrin(ogen) degradation products to account for the effects observed. 1 Weijers et al. 2 raise the possibility that intact fibrinogen is converted to fibrin by thrombin when added to the conditioned medium of the cultured endothelial cells. To address this concern, we show additional data collected from control experiments over the course of our studies (Fig. 1) . To determine whether thrombin activity affected permeability induced by intact fibrinogen, we assessed FITC-Dextran flux across the endothelial barrier as described 1 in the absence and presence of the specific thrombin inhibitor, hirudin. As shown in Figure 1a , 1 Unit/ml hirudin had no effect on the flux of FITC-Dextran across the endothelial barrier (p ¼ 0.14, Student's t-test), indicating that active thrombin was not participating in fibrinogen-induced endothelial permeability. Higher concentrations of hirudin (up to 5 Units/ml) also had no effect on endothelial barrier permeability (unpublished data).

To address the suggestion that the soluble, intact fibrinogen was converted to fibrin and/or fibrin(ogen) degradation products by the malignant breast epithelial cells, we show data collected by Dr. Brian Rybarczyk that was published in his doctoral dissertation. 5 Iodinated fibrinogen exposed to MDA-MB-231 cells for 18 hr remained intact at 340 kDa; it was not cleaved by thrombin or crosslinked to form fibrin(ogen) polymers, nor were typical proteolytic degradation products (e.g., plasmin-derived fragments D and E) observed (Fig.  2a) . Data published from our laboratory indicate that fibrinogen added exogenously to fibroblasts (please see Fig. 7 in Ref. 4) or endogenously produced by A549 lung epithelial cells (please see Fig. 9 in Ref. 4) remains intact. Additional data from our laboratory suggest that cell-associated fibrinogen interacts with cell surface integrins a5b1 and avb3, either directly or indirectly through association with fibronectin and with cell surface heparan sulfate proteoglycans (HSPGs). [5] [6] [7] It is widely accepted by others 2,8-10 and us 11 that residues defined by fibrinogen-b are cryptic in intact fibrinogenthe fibrin-specific monoclonal antibody T2G1 8 will not bind to its epitope, defined by residues b, 15-21 when intact fibrinogen is presented either in solution or adsorbed to a solid surface. However, we have shown that when highly purified intact fibrinogen is added to the solution phase of metabolically active cells in culture, fibrinogen assembles into the extracellular matrix in the absence of proteolytic cleavage to fibrin, fibrin(ogen) degradation products, or processed into higher ordered structures such as covalently cross-linked fibrin(ogen). 4, 6, 7, 12 This was observed using both primary cells (human foreskin fibroblasts and human umbilical vein endothelial cells) as well as human cell lines, including lung type II-like A549 epithelial cells, and nonmalignant (HBL100) and malignant (MDA-MB-231) breast epithelial cells. Moreover, we have shown conclusively that b 15-21 exposed in fibrillar matrix fibrinogen is recognized by mono-clonal antibody T2G1 (Fig. 2 , reproduced with permission from Blood, 2003;102:4035-43; Cover photo). 7 Palumbo et al. [13] [14] [15] [16] [17] have performed elegant experiments in mutant mice to show that plasma fibrin(ogen), thrombin and platelets are all important in promoting metastasis of certain 

Letters to the Editor cancers to the lung. Pertinent to this response are their results showing that, in fibrinogen-deficient mice, the number of metastatic foci of B16-BL6 melanoma and Lewis Lung carcinoma was greatly reduced in lung. 13, 14 Weijers et al. 2 raise the point that when Palumbo and colleagues performed the above experiments in the absence or presence of the specific thrombin inhibitor hirudin, lung metastasis was reduced 20fold in hirudin-treated wild-type mice (please see Fig. 5 in Ref. 13 ). However, hirudin also decreased lung metastasis comparably in fibrinogen-deficient mice (please see Fig. 5 in Ref. 13) , suggesting that the prometastatic affects of thrombin were, for the most part, fibrinogen independent. It is well known that thrombin contributes to the severity of cancer progression by promoting tumor angiogenesis, cancer cell proliferation and metastasis by mechanisms other than just thrombin generation of fibrin. 18 The neo-NH 2 -terminus of the fibrin b chain, defined by residues 15-42, participates in clot formation and also has been implicated in a number of important cellular responses including cell spreading, 19 stimulating cell proliferation, 20 binding to VE-cadherin to support angiogenesis, 21 binding to endothelial cell HSPGs 22 and inducing cell migration during wound repair. 7 We have shown that a cryptic heparan binding domain maps to b 15-42 residues of fibrin(ogen). 23 Because the VE-cadherin binding domain and heparan binding domain on fibrin(ogen) overlap on the fibrinogen b chain, we cannot rule out the possibility that endothelial cell surface HSPGs play a role in intact fibrinogen-induced endothelial permeability. However, we consider this the least favorable interpretation of our data because heparin-dependent binding Letters to the Editor of fibrin monomer to endothelial cells occurred only when the endothelial cells were fixed to the ELISA plate during the cell binding assay. In contrast, fibrinogen bound poorly to fixed endothelial cells in this cell binding assay. 22 Furthermore, we have shown that fibrinogen assembly into the extracellular matrix requires binding to the cell surface before deposition into the matrix (please see Fig. 9 in Ref. 5). Such cell surface binding is integrin dependent, requiring fibrinogen Aa-chain RGD sequences. However, this cell surface binding is not HSPG dependent in that desBb 1-42 -fibrinogen, also known as fibrinogen-325, still assembles into matrix fibrils (please see Figs. 3-5 in Ref. 7) . Moreover, only metabolically active cells are capable of assembling fibrinogen into mature matrix fibrils (please see Fig. 1 in Ref. 24 ). Taken together, these published data support our conclusion that in the absence of malignant breast cancer cells, endothelial barrier permeability occurs only after intact fibrinogen binds to integrins on the endothelial cell surface. Binding induces a conformational change exposing the fibrinogen b 15-42 domain, thus allowing it to bind to VE-cadherin. This conclusion is further supported by the photomicrograph (Fig. 3 and cover photo for Sahni et al. 1 ) showing that fibrinogen assembles into subendothelial matrix fibrils and binds to the surface of endothelial cells at cell-to-cell junctions where VEcadherin is found.

We agree that fibrin and thrombin play significant physiologic roles in cancer metastasis. However, the exact structure of fibrin(ogen) and fibrin(ogen) degradation products that promote endothelial barrier permeability is poorly understood. We pose the intriguing possibility that subphysiological levels of fibrinogen modulate cell responses in the microenvironment where fibrinogen, tumor cells and endothelium interact. Extensive research from our laboratory has contributed to elucidating molecular mechanisms regulating gene expression, protein biosynthesis and assembly, and function of fibrinogen produced by extrahepatic epithelium from the lung, prostate and breast using adenocarcinoma cell lines. 4, 5, [25] [26] [27] [28] [29] [30] Others have reported expression of the fibrinogen genes and secretion of fibrinogen protein by intestinal and cervical epithelial cancer cell lines. 31, 32 Extrahepatic expression of fibrinogen occurs in vivo, as demonstrated in animal models of Pneumocystis carinii pneumonia, and by gene expression profiling of biopsy samples from patients with lung or breast cancer. [33] [34] [35] [36] [37] [38] [39] The functional significance of fibrinogen expression by extrahepatic epithelium is likely influenced more by the cellular context in which the fibrinogen is found rather than by its overall plasma concentration.

In summary, we stand by our interpretation that exposure of the VE-cadherin binding domain in intact fibrinogen induces endothelial cell permeability and promotes transendothelial migration of malignant breast cancer cells in vitro. 1 Furthermore, it is reasonable to hypothesize that small amounts of fibrinogen produced endogenously by breast cancer cells contribute to tumor cell-endothelial cell interactions to promote breast cancer metastasis in vivo. The striking ob-servation that intact fibrinogen was unable to induce barrier endothelial permeability in the presence of MCF-10A nonmalignant breast epithelial cells (please see Fig. 6 and Discussion in Ref. 1) led us to further hypothesize that nonmalignant breast epithelial cells bind fibrinogen b 15-42 sequences, likely through cell surface HSPGs, rendering the VE-cadherin binding domain at fibrinogen b 15-42 inaccessible. The ability of nonmalignant breast epithelial cells to bind fibrinogen b and the loss of such binding capacity by malignant breast cancer cells suggests a molecular mechanism by which premalignant breast epithelial cells transform to a highly aggressive metastatic breast cancer phenotype. Further studies in animal models of breast cancer metastasis will permit us to test the validity of these hypotheses.

The VEcadherin binding domain of fibrinogen induces endothelial barrier permeability and enhances transendothelial migration of malignant breast epithelial cells

Fibrinogen induces endothelial cell permeability

Specificity of a monoclonal antibody for the NH2-terminal region of fibrin

Fibrinogen and fibrin structure and functions

Thrombin cleavageindependent deposition of fibrinogen in extracellular matrices

Involvement of Rho kinase in endothelial barrier maintenance

Fibrinogen degradation product fragment D increases endothelial monolayer permeability

Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells

Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogendeficient mice

The VEcadherin binding domain of fibrinogen induces endothelial barrier permeability and enhances transendothelial migration of malignant breast epithelial cells

Fibrin b15-42 domain is cryptic in intact fibrinogen: comment on the study by A. Sahni et al. Int J Cancer

The role of adherens junctions and VE-cadherin in the control of vascular permeability

Thrombin cleavageindependent deposition of fibrinogen in extracellular matrices

Fibrinogen and the extracellular matrix: biological implications in breast cancer

The incorporation of fibrinogen into extracellular matrix is dependent on active assembly of a fibronectin matrix

Matrix-fibrinogen enhances wound closure by increasing both cell proliferation and migration

Specificity of a monoclonal antibody for the NH 2 -terminal region of fibrin

Accessibility of epitopes on fibrin clots and fibrinogen gels

Plasmic degradation of fibrin rapidly decreases platelet adhesion and spreading

Cloning of the complete coding sequence of rat fibrinogen Bb chain cDNA: interspecies conservation of fibrin b15-42 primary structure

Cell surface heparan sulfate proteoglycan-dependent fibrinogen assembly in extracellular matrix

Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells

Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogendeficient mice

Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells

Mechanisms linking tumor cell-associated procoagulant function to tumor metastasis

Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent andindependent mechanisms

Thrombin induces tumor growth, metastasis, and angiogenesis: evidence for a thrombin-regulated dormant tumor phenotype

Endothelial cell spreading on fibrin requires fibrinopeptide B cleavage and amino acid residues 15-42 of the b chain

Cell proliferation on fibrin: modulation by fibrinopeptide cleavage

VE-Cadherin mediates endothelial cell capillary tube formation in fibrin and collagen gels

Heparin-binding domain of fibrin mediates its binding to endothelial cells

Thrombin cleavage enhances exposure of a heparin binding domain in the N-terminus of the fibrin b chain

Fibrinogen modulates gene expression in wounded fibroblasts

Polarized secretion of fibrinogen by lung epithelial cells

Induction of fibrinogen biosynthesis and secretion from cultured pulmonary epithelial cells

Cell type-specific regulation of fibrinogen expression in lung epithelial cells by dexamethasone and IL-1b

Fibrinogen assembly, secretion, and deposition into extracellular matrix by MCF-7 human breast carcinoma cells

Cell type-specific differential induction of the human V C -fibrinogen promoter by IL-6

Fibrinogen synthesized by cancer cells augments the proliferative effect of FGF-2

Identification and biosynthesis of fibrinogen in human uterine cervix carcinoma cells

Evidence for an acute phase response in human intestinal epithelial cells

Tissue-specific and ubiquitous expression of fibrinogen V C -chain mRNA

Developmental expression of mRNAs encoding platelet proteins in rat megakaryocytes

Cloning and characterization of a lung-specific cDNA corresponding to the V C chain of hepatic fibrinogen

Induction of fibrinogen expression in the lung epithelium during Pneumocystis carinii pneumonia

Gene regulation in an MCF-7 cell line that naturally expresses an estrogen receptor unable to directly bind DNA

The severe acute respiratory syndrome coronavirus 3a protein up-regulates expression of fibrinogen in lung epithelial cells

Functional activation of the formyl peptide receptor by a new endogenous ligand in human lung A549 cells

Abha Sahni